Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22911402 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL21472138 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL20466154 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL17480704 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL17971017 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL24788338 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL12284667 | 0.98 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL18822408 | 0.94 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL19050974 | 0.92 | KDM4E (0.39) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL9541679 | 0.88 | KDM4E (0.45) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KDM4E 2053/4885ALDH1A1 2958/4885MEN1 2058/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | KDM4E 2704/4885ALDH1A1 2567/4885MEN1 3483/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KDM4E 2053/4885ALDH1A1 2958/4885MEN1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.